Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Conditions
- NSCLC Stage II
- NSCLC, Stage IIIA
- NSCLC Stage IIIB
Interventions
- DRUG: Atezolizumab 1200 mg abs day 1 q22 (iv)
Sponsor
University Hospital Heidelberg
Collaborators